NCT00516490

GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 570 (actual)
• Sponsor: V.K.V. American Hospital, Istanbul · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

A single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles was reported to increase pregnancy and birth rates. This study was done to evaluate the reproducibility of previous findings.

Detailed description

GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the long GnRH agonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a long GnRH agonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.

Conditions

• Infertility

Interventions

Type	Name	Description
DRUG	triptorelin acetate	Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
DRUG	Na Cl %0.9	0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer

Timeline

• Start date: 2006-09-01
• Completion: 2007-07-01
• First posted: 2007-08-15
• Last updated: 2007-08-15

Locations

1 site across 1 country: Turkey (Türkiye)